Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration

Andrea CALCAGNO; C Pinnetti; A De Nicolò; E Scarvaglieri; M Gisslen; M Tempestilli; D'Avolio Antonio; V Fedele; G Di Perri; A Antinori; S Bonora

doi:10.1111/bcp.13552

Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration

Andrea CALCAGNO, C Pinnetti, A De Nicolò, E Scarvaglieri, M Gisslen, M Tempestilli, D'Avolio Antonio, V Fedele, G Di Perri, A Antinori, S Bonora

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Abacavir is a widely used nucleotide reverse transcriptase inhibitor whose cerebrospinal fluid (CSF) exposure has been previously assessed in twice-daily recipients. We studied abacavir CSF concentrations in 61 and 9 HIV-positive once-daily and twice-daily abacavir intakers. Patients on once-daily abacavir had higher plasma and CSF concentrations (96 vs. 22 ng/mL, p=0.038 and 123 vs. 49 ng/mL, p=0.038) but similar CSF-to-plasma ratios (0.8 vs. 0.5, p=0.500). CSF abacavir concentrations were adequate in once-daily receiving patients.

Lingua originale	Inglese
pagine (da-a)	1-4
Numero di pagine	4
Rivista	British Journal of Clinical Pharmacology
Volume	1
Numero di pubblicazione	1
DOI	https://doi.org/10.1111/bcp.13552
Stato di pubblicazione	Pubblicato - 2018

Keywords

abacavir
age
central nervous system
cerebrospinal fluid
pharmacokinetics
protease inhibitors

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1111/bcp.13552

https://hdl.handle.net/11579/216885

Altri file e collegamenti

handle

Cita questo

@article{1145539a8dbe4d488d9f37e5d72f9bb7,

title = "Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration",

abstract = "Abacavir is a widely used nucleotide reverse transcriptase inhibitor whose cerebrospinal fluid (CSF) exposure has been previously assessed in twice-daily recipients. We studied abacavir CSF concentrations in 61 and 9 HIV-positive once-daily and twice-daily abacavir intakers. Patients on once-daily abacavir had higher plasma and CSF concentrations (96 vs. 22 ng/mL, p=0.038 and 123 vs. 49 ng/mL, p=0.038) but similar CSF-to-plasma ratios (0.8 vs. 0.5, p=0.500). CSF abacavir concentrations were adequate in once-daily receiving patients.",

keywords = "abacavir, age, central nervous system, cerebrospinal fluid, pharmacokinetics, protease inhibitors, abacavir, age, central nervous system, cerebrospinal fluid, pharmacokinetics, protease inhibitors",

author = "Andrea CALCAGNO and C Pinnetti and \{De Nicol{\`o}\}, A and E Scarvaglieri and M Gisslen and M Tempestilli and D'Avolio Antonio and V Fedele and \{Di Perri\}, G and A Antinori and S Bonora",

year = "2018",

doi = "10.1111/bcp.13552",

language = "English",

volume = "1",

pages = "1--4",

journal = "British Journal of Clinical Pharmacology",

issn = "0306-5251",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "1",

}

TY - JOUR

T1 - Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration

AU - CALCAGNO, Andrea

AU - Pinnetti, C

AU - De Nicolò, A

AU - Scarvaglieri, E

AU - Gisslen, M

AU - Tempestilli, M

AU - Antonio, D'Avolio

AU - Fedele, V

AU - Di Perri, G

AU - Antinori, A

AU - Bonora, S

PY - 2018

Y1 - 2018

N2 - Abacavir is a widely used nucleotide reverse transcriptase inhibitor whose cerebrospinal fluid (CSF) exposure has been previously assessed in twice-daily recipients. We studied abacavir CSF concentrations in 61 and 9 HIV-positive once-daily and twice-daily abacavir intakers. Patients on once-daily abacavir had higher plasma and CSF concentrations (96 vs. 22 ng/mL, p=0.038 and 123 vs. 49 ng/mL, p=0.038) but similar CSF-to-plasma ratios (0.8 vs. 0.5, p=0.500). CSF abacavir concentrations were adequate in once-daily receiving patients.

AB - Abacavir is a widely used nucleotide reverse transcriptase inhibitor whose cerebrospinal fluid (CSF) exposure has been previously assessed in twice-daily recipients. We studied abacavir CSF concentrations in 61 and 9 HIV-positive once-daily and twice-daily abacavir intakers. Patients on once-daily abacavir had higher plasma and CSF concentrations (96 vs. 22 ng/mL, p=0.038 and 123 vs. 49 ng/mL, p=0.038) but similar CSF-to-plasma ratios (0.8 vs. 0.5, p=0.500). CSF abacavir concentrations were adequate in once-daily receiving patients.

KW - abacavir

KW - age

KW - central nervous system

KW - cerebrospinal fluid

KW - pharmacokinetics

KW - protease inhibitors

KW - abacavir

KW - age

KW - central nervous system

KW - cerebrospinal fluid

KW - pharmacokinetics

KW - protease inhibitors

UR - https://iris.uniupo.it/handle/11579/216885

U2 - 10.1111/bcp.13552

DO - 10.1111/bcp.13552

M3 - Article

SN - 0306-5251

VL - 1

SP - 1

EP - 4

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

IS - 1

ER -

Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo